- Home
- AGIO vs LEG Comparison
AGIO vs LEG Comparison
Compare AGIO & LEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- LEG
- Stock Information
- Founded
- AGIO 2007
- LEG 1883
- Country
- AGIO United States
- LEG United States
- Employees
- AGIO N/A
- LEG N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- LEG Home Furnishings
- Sector
- AGIO Health Care
- LEG Consumer Discretionary
- Exchange
- AGIO Nasdaq
- LEG Nasdaq
- Market Cap
- AGIO 1.4B
- LEG 1.2B
- IPO Year
- AGIO 2013
- LEG N/A
- Fundamental
- Price
- AGIO $39.23
- LEG $10.00
- Analyst Decision
- AGIO Buy
- LEG Hold
- Analyst Count
- AGIO 6
- LEG 4
- Target Price
- AGIO $58.60
- LEG $10.50
- AVG Volume (30 Days)
- AGIO 615.0K
- LEG 3.0M
- Earning Date
- AGIO 07-31-2025
- LEG 07-31-2025
- Dividend Yield
- AGIO N/A
- LEG 2.01%
- EPS Growth
- AGIO N/A
- LEG N/A
- EPS
- AGIO 11.45
- LEG N/A
- Revenue
- AGIO $37,035,000.00
- LEG $4,308,800,000.00
- Revenue This Year
- AGIO $22.30
- LEG N/A
- Revenue Next Year
- AGIO $219.19
- LEG $1.98
- P/E Ratio
- AGIO $3.39
- LEG N/A
- Revenue Growth
- AGIO 25.96
- LEG N/A
- 52 Week Low
- AGIO $23.42
- LEG $6.48
- 52 Week High
- AGIO $62.58
- LEG $14.24
- Technical
- Relative Strength Index (RSI)
- AGIO 70.51
- LEG 58.40
- Support Level
- AGIO $34.60
- LEG $9.53
- Resistance Level
- AGIO $40.06
- LEG $10.59
- Average True Range (ATR)
- AGIO 1.45
- LEG 0.38
- MACD
- AGIO 0.43
- LEG 0.06
- Stochastic Oscillator
- AGIO 88.98
- LEG 66.94
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About LEG Leggett & Platt Incorporated
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.